Artificial intelligence fears could lead to over-regulation

, | | November 8, 2017
value alignment hands x
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

[A]s we begin to realise [artificial intelligence] opportunities, the potential risks increase: that AI will proliferate, uncontrolled and unregulated, in the hands of a few increasingly powerful technology firms, at the expense of jobs, equality and privacy. Already, mistakes over the sharing of patient records between DeepMind and the Royal Free Hospital in London have raised public concerns about technology firms being involved in digital healthcare.

Private companies will continue to use AI, unregulated, to improve the targeting of products. But in the public sector where there could be life-changing benefits, over-regulation will mean the opportunities will be lost. That is not to say that AI should be allowed to spread uncontrolled in the NHS. But it does emphasise why it’s so important to get this right. AI can only be introduced successfully in the NHS if the public, patients and healthcare professionals have confidence in the system, including clear oversight and accountability.

While there is a risk that a GM-style backlash could prevent the appropriate application of AI in healthcare, we should not give up hope. As the Information Commissioner has recently emphasised, it does not need to be a choice between privacy or innovation.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: Why we can’t leave AI in the hands of Big Tech

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend